DDInter741 DDInter122
Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder drug by Sprout Pharmaceuticals. Flibanserin's mechanism of action is attributed to its high affinity for 5-HTA1 and 5-HTA2 receptors, displaying agonist activity on 5-HTA1 and antagonist on 5-HTA2, resulting in lowering of serotonin in the brain as well as an effect on increasing norepinephrine and dopamine neurotransmitters.
Artesunate is indicated for the initial treatment of severe malaria. The World Health Organization recommends artesunate as first line treatment for severe malaria. Artesunate was developed out of a need for a more hydrophilic derivative of [artemisinin]. Artesunate was granted FDA approval on 26 May 2020.
Flibanserin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Flibanserin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Flibanserin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rolapitant
Flibanserin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Phenindamine
Flibanserin {u} may lead to a major life threatening interaction when taken with {v} Chloramphenicol
Flibanserin {u} may lead to a major life threatening interaction when taken with {v} Edoxaban
Flibanserin may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Flibanserin may cause a minor interaction that can limit clinical effects when taken with Bortezomib
Flibanserin may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant
Flibanserin may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine
Flibanserin may lead to a major life threatening interaction when taken with Chloramphenicol
Flibanserin may lead to a major life threatening interaction when taken with Edoxaban